Ep. 376 - M&A momentum: 3Q public markets preview

M&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss BioCentury’s 3Q26 Public Markets Preview, asking whether M&A momentum can carry biotech through year-end and what happens if the AI trade goes bust?
Editor in Chief Simone Fishburn gives her perspective on what incoming Prime Minister Andy Burnham’s agenda means for U.K. life sciences. The analysts also discuss Ionis’ ATTR-CM miss and Takeda’s orexin program. This episode of the BioCentury This Week podcast has been brought to you by CBRE.

View full story: https://www.biocentury.com/article/660118

#BiotechMA #BiotechInvesting #PublicMarkets #LifeSciences #DrugDevelopment

00:01 - Sponsor Message: CBRE
01:46 - 3Q Market Preview
10:54 - Burnham’s Britain
19:40 - Ionis' ATTR-CM Miss
29:12 - Takeda Orexin Program

To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

Reach us by sending a text